Amit Sachdev - 06 Feb 2024 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP Chief Patient & Ext Af Off
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
06 Feb 2024
Transactions value $
$0
Form type
4
Filing time
08 Feb 2024, 16:43:12 UTC
Previous filing
17 Nov 2023
Next filing
13 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +5.81K +9.89% $0.00 64.6K 06 Feb 2024 Direct F1
transaction VRTX Common Stock Award $0 +7.87K +12.17% $0.00 72.5K 06 Feb 2024 Direct F2
transaction VRTX Common Stock Award $0 +7.11K +9.81% $0.00 79.6K 07 Feb 2024 Direct F3
holding VRTX Common Stock 882 06 Feb 2024 401(k)
holding VRTX Common Stock 6.57K 06 Feb 2024 Held in Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024.
F2 Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest in installments beginning on 02/10/2024.
F3 Restricted stock unit award that vests in installments beginning on 02/17/2025.